SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a number one supplier of autoimmune testing options, introduced at the moment that Tina S. Nova, Ph.D. has been elected as Govt Chair of the Exagen Board of Administrators, efficient January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Administrators at Exagen since 2018, and who will stay a member of the Board.
Dr. Nova at present serves as President of Veracyte’s (Nasdaq: VCYT) U.S. CLIA enterprise the place she leads all features of the corporate’s broad menu of diagnostic laboratory exams. She beforehand held the place of President & CEO of Decipher Biosciences till March 2021, when Veracyte bought the group for $600 million. She has held quite a few management roles within the life science trade, which embrace CEO of Molecular Stethoscope and SVP & Normal Supervisor of Oncology at Illumina. Dr. Nova was the co-founder, President & CEO of Genoptix, which was bought by Novartis AG for $470 million in 2011. She has additionally held senior positions with Nanogen, Inc., Ligand Prescribed drugs, Inc. and Hybritech.
“I’m excited to welcome Tina as Govt Chair at Exagen. Her broad expertise with revolutionary healthcare corporations and management in rising organizations with proprietary know-how shall be invaluable to Exagen as we glance to increase our place because the premier supplier of autoimmune testing options,” mentioned John Aballi, President and CEO of Exagen. “I’ve had the pleasure of working with Tina for nearly 15 years, and I’m thrilled to work intently along with her once more as we proceed to form the way forward for Exagen.”
“I’m honored to have been elected Govt Chair and I’m excited to tackle this extra management position at Exagen,” mentioned Dr. Nova. “I additionally wish to thank Brian Birk, who served as the corporate’s Chair since 2018. Brian was instrumental in rising the group into a pacesetter in autoimmune testing and I’m happy that he’ll stay a member of the Board.”
Dr. Nova at present serves on the Board of Azenta (Nasdaq: AZTA) and beforehand served on the Board of Administrators of Veracyte and Enviornment Prescribed drugs. Dr. Nova holds a Ph.D. in Biochemistry from the College of California, Riverside and a B.S. in Organic Sciences from the College of California, Irvine.
Exagen (Nasdaq: XGN) is a number one supplier of autoimmune diagnostic, prognostic, and monitoring testing options. Exagen is a affected person targeted, discovery pushed group constructed on the success of AVISE testing and is investing in its product pipeline to assist sufferers all through their autoimmune prognosis and therapy journeys. The objective at Exagen is to help sufferers, physicians, and payors by enabling precision drugs. Exagen is situated in San Diego County with medical and analysis and improvement laboratories in Vista, CA.
Exagen cautions you that statements contained on this press launch concerning issues that aren’t historic details are forward-looking statements. These statements are primarily based on Exagen’s present beliefs and expectations. Such forward-looking statements embrace, however will not be restricted to, statements concerning: Exagen’s objectives and methods; the potential utility and effectiveness of Exagen’s companies and testing options which are at present obtainable or in its improvement pipeline; the anticipated advantages of Dr. Nova’s place with Exagen; and Exagen’s potential progress and success and its skill to proceed to develop and succeed. The inclusion of forward-looking statements shouldn’t be thought to be a illustration by Exagen that any of its plans shall be achieved. Precise outcomes could differ from these set forth on this press launch because of the dangers and uncertainties inherent in Exagen’s enterprise, together with, with out limitation: the COVID-19 pandemic could proceed to adversely have an effect on its enterprise, monetary situation and outcomes of operations, together with on account of slowdown in its operations in addition to these of its suppliers and courier companies, impeding affected person motion and interruptions to healthcare companies inflicting a lower in take a look at volumes, disruptions to the provision chain of fabric wanted for its exams inflicting a rise in price per take a look at, its gross sales and commercialization actions and its skill to obtain specimens and carry out or ship the outcomes from its exams, delays in reimbursement and protection selections from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and deliberate medical trials involving its exams; Exagen’s industrial success relies upon upon attaining and sustaining important market acceptance of its testing merchandise and promoted therapeutics amongst rheumatologists, sufferers, third-party payors and others within the medical neighborhood; Exagen’s skill to efficiently execute on its enterprise methods; third-party payors not offering protection and satisfactory reimbursement for Exagen’s testing merchandise or promoted therapeutics, together with Exagen’s skill to gather funds due; Exagen’s skill to acquire and keep mental property safety for its testing merchandise; regulatory developments affecting Exagen’s enterprise; and different dangers described in Exagen’s prior press releases and Exagen’s filings with the Securities and Trade Fee (“SEC”), together with underneath the heading “Threat Components” in Exagen’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2021 and any subsequent filings with the SEC. You might be cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date hereof, and Exagen undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion, which is made underneath the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995.
Kamal Adawi, Chief Monetary Officer